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Sinumuary Flavone acetic acid (FAA), 8.6gm 2 has been administered by 6h intravenous infusion to 19
patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug
associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in
either disease.
FAA is the second of a series of compounds based on the
flavonoid aglycone ring structure to undergo clinical evalu-
ation in malignant disease. The parent compound (flavone
acetic acid ester; LM985) was not recommended for phase II
assessment because of drug associated acute hypotension and
the fact that it appeared to function as a prodrug with rapid
hydrolysis in vivo to FAA (Kerr et al., 1986).
Preclinical studies with FAA indicate that it is active
against a broad spectrum of murine transplantable solid
tumours which tend, on the whole, to be refractory to
conventional cytotoxic agents. These included a range of
colon adenocarcinomas, pancreatic ductal adenocarcinoma,
mammary adenocarcinoma and Glasgow's osteosarcoma
(Corbett et al., 1986; Zaharko et al., 1986).
Precinical pharmacology (Zaharko et al., 1986) implied a
plasma concentration threshold for activity and toxicity in
mice and dogs, the plasma concentrations achieved in man
in the phase I study were similar to those which were active
in murine tumour models. Clinical phase I trials were
conducted using both 1 h and 6h infusions given weekly. At
maximum tolerated doses - 6.4gm-2 over I h and 10g m-2
over 6h - toxicity included hypotension, diarrhoea and
intolerable warmth and flushing (Kerr et al., 1987). A phase
II trial programme has been planned in Europe using both
I h (4.8gm-2) and 6h (8.6gm-2) schedules. We report here
a phase II study of FAA, 8.6gm -2, administered by 6h
infusion to patients with advanced malignant melanoma and
colorectal carcinoma. This was conducted under the auspices
of the Cancer Research Campaign phase I/II trials
committee.
Patients and methods
Common eligibility criteria for these two disease specific
protocols required that the patients have measurable disease,
a performance status of 2 or less, life expectancy greater
than 2 months, age under 75 years, appropriate haemato-
logical (haemoglobin > l0g %, WBC >3,000mm -3 and
platelets > 00,000mm-3) and biochemical (bilirubin
<20 umol1- I and creatinine < 150pmol 1-1) parameters, no
radiotherapy during the preceding 4 weeks, no previous
malignancy at other sites (except in situ cancer of cervLx and
adequately treated basal cell carcinoma of the skin) and no
serious intercurrent non-malignant disease. The patients with
malignant melanoma had not received prior chemotherapy
while those with colorectal carcinoma had received no
chemotherapy in the 4 weeks preceding treatment (6 weeks
in the case of nitrosoureas and mitomycin C).
Flavone acetic acid was supplied by Lipha Lyonnaise
Industrielle, dissolved in I litre of 0.9% saline and infused
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over 6h. A total of 500ml of 1.26% NaHCO3 was infused
over I h immediately before and after drug infusion in order
to establish an alkaline diuresis. The drug was given every
week for 6 consecutive weeks, haematological and bio-
chemical parameters permitting. Blood pressure measure-
ments were taken half-hourly during treatment and for an
hour after the infusion finished.
Standard WHO response criteria were used where appro-
priate and in the absence of progressive disease or serious
toxicity a further treatment course could be administered.
WHO grades were not used for flushing, visual disturbance
and hypotension. Arbitrary grades of I, mild, II, moderate
and III, severe were substituted. Hypotension was graded as
I if baseline <110mm, up to 10% drop, or if baseline
>110mm, up to 20mm drop; HI if baseline <110mm, 10-
20% drop, or if baseline >110mm, 20-40mm drop; III if
baseline <110mm, more than 20% drop, or if baseline
>110mm, more than 40mm drop. Patients in whom rapid
disease progression occurred were considered eligible for
response assessment if they had received a minimum of three
doses at weekly intervals. Informed consent was obtained
from all patients according to regulations determined by
local ethical committees.
Results
A total of 19 patients with colorectal carcinoma and 15
patients with malignant melanoma were entered in the trial.
One patient with malignant melanoma (having received prior
chemotherapy) was considered ineligible for the study. All
but four of the eligible colorectal patients, who received only
one or two courses due to rapid disease progression or drug
toxicity, were evaluable for therapeutic response. The charac-
teristics of evaluable patients are summarised in Tables I and
II.
Treatment associated toxicity is shown in Table III.
Overall, the toxicity as reported was mild. However, two
patients were withdrawn from the study, one with drug
associated hypotension and the other with grade IV
haematological toxicity. The first patient had a drop in
systolic blood pressure from 130 to 85mmHg, I h after the
second infusion commenced. The drug infusion was stopped
and his blood pressure returned to normal after 1.5h and no
further drug treatment was given. The second patient had an
episode of profound thrombocytopenia which developed
shortly after her fifth cycle of FAA. Her platelet count fell
to 1,000mm-3, she had spontaneous vaginal bleeding and
required platelet transfusion. The patient recovered and
subsequent investigations identified 1 gG and I gM anti-
bodies to FAA on the patient's platelets. She had previously
been treated in another study with a monoclonal antibody
directed against carcino embryonic antigen and she had
developed antimouse antibodies (Davis et al., 1988). In terms
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Table I Charactenrstics of evaluable colorectal patients
Characteristic No. ofpatients
Male/females 10/5
Median age (years) 51
Range 42-71
Median performance status I
Range 0-2
Median no. of weekly courses given 6
Range 4-9
Previous surgery 15
Previous radiotherapy 4
Previous chemotherapy 6
Site of measurable disease
Primary,,regional recurrence nodes 9
Liver 12
Lung 3
TblIk Characteristics of evaluable malignant melanoma patients
Characteristic No. ofpatients
Male/females 5/9
Median age (years) 48
Range 28-69
Median performance status 0
Range 0-2
Median no. of weekly courses given 5
Range 3-6
Previous surgery 14
Site of measurable disease
Nodes soft tissue skin 24
Lung 3
Liver'intra-abdominal 5
Other 2
Table III Patterns of toxicity for melanoma and colorectal carci-
noma patients (usually consistent within patients and from week to
week)
Nunber ofpatients in grade
Toxicity I II III IV
Nausea and vomiting 8 5 1
Constipation 3 1 - -
Diarrhoea 6 - -
Hypotension' 3 5 - -
Muscle pain 7 3 -
Flushing' 3 - -
Visual disturbance' 3
Conscious state 3
Haematological - - -
Total number of evaluable patients=29. WHO grades were used
unless otherwise specified.
'These forms of toxicity were coded by an arbitrary scale defined
in the Methods section.
of chronic toxicity, one female patient with colorectal cancer
developed severe persistent postural hypotension after com-
pleting treatment. Investigations performed in the MRC
Blood Pressure Unit, Western Infirmary, Glasgow, indicated
that she had developed an autonomic neuropathy presum-
ably related to FAA treatment (Lewis et al., 1988). She had
good symptomatic control with fludriocortisone.
In terms of disease response, 13 of the melanoma patients
progressed on treatment and one had stable disease at the
end of treatment. Nine of the evaluable colorectal patients
progressed on treatment and six had stable disease at the end
of treatment.
Despite promising preclinical activity, FAA (8.6gm2 over
6h) has no demonstrable clinical activity in advanced malig-
nant melanoma and colorectal carcinoma. This result is
similar to that reported by the Early Clinical Trials Group
of the EORTC who found no activity in phase II trials in
four tumour types using 4.8gm 2 over 1 h (Kaye et al.,
1989). In the phase I trial, the pharmacokinetic profiles
indicated that 'effective drug exposure', as assessed by the
area under the plasma concentration time curve
>lOOpgml-F, was approxcimately 50% greater for the 6h
infusion. Despite this apparent pharmacokinetic advantage,
the 6h infusion is also clinically inactive.
The toxicity associated with the phase II tnrals was similar
to that predicted by the phase I trial. One patient suffered
persistent toxicity in the form of postural hypotension
caused by autonomic neuropathy, presumably related to
treatment with FAA (Lewis et al., 1988) but no other 'late'
toxicity has been seen.
The mechanism of action of FAA is unknown. There is
only minimal damage to DNA, as assessed by alkaline
elution (Bissery et al., 1988). However, there is some evi-
dence to suggest the FAA can induce haemorrhagic necrosis
in murine colonic tumours (Smith et al., 1987) and decrease
blood flow in subcutaneously implanted Glasgow's osteo-
sarcoma as demonstrated by 31P nuclear magnetic response
spectroscopy (Evelhoch et al., 1988). In view of the clinical
effects of FAA on blood pressure it is tantalising to hypothe-
sise that differences in the regulation of tumour and systemic
blood flow, between mouse and man, could contribute to
FAA's inactivity clinically. In addition, FAA systemically
augments natural killer cell activity in normal and tumour
bearing mice and in human cancer patients, possibly by
induction of z and P interferon (Horning et al., 1988), but
the clinical relevance of these observations is unknown.
Although there are differences in plasma binding of FAA
comparing mouse and man, the plasma concentrations
achieved at the recommended phase II doses are similar to
those active in murine tumour models. FAA is extensively
metabolised to glucoronides in patients, but not mice, and
the drug has a higher relative plasma clearance in humans (J.
Cummings, personal communication). It would be interesting
to compare tumour FAA concentrations in mouse and man,
but it seems more likely that its clinical inactivity may relate
to differences in its biological effects in murine and human
tumour systems.
This study was conducted on behalf of the Cancer Research
Campaign Phase II Clinical Tnrals Committee and supported by
Lipha Lyonnaise Industrielle Ltd. DJ.K. is supported by the CRC
and would like to thank Fiona Conway for typing the manuscript.
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